Nantahala reports 9.99% stake in Opus Genetics
Nantahala Capital Management and its principals report a significant passive stake in Opus Genetics, Inc. As of December 31, 2025, they may be deemed to beneficially own 7,123,506 shares of common stock, representing 9.99% of the outstanding class.
Rhea-AI Filing Summary
Nantahala Capital Management and its principals report a significant passive stake in Opus Genetics, Inc. As of December 31, 2025, they may be deemed to beneficially own 7,123,506 shares of common stock, representing 9.99% of the outstanding class.
This figure includes 2,342,176 shares that can be acquired within sixty days through warrant exercises. All voting and dispositive powers over the 7,123,506 shares are described as shared among Nantahala, Wilmot B. Harkey, and Daniel Mack, primarily through funds and separately managed accounts they oversee.
Blackwell Partners LLC - Series A, a fund advised by Nantahala, has the right to receive dividends or sale proceeds on more than five percent of the outstanding common stock. The reporting persons certify the holdings are in the ordinary course of business and not for changing or influencing control of Opus Genetics.
Positive
- None.
Negative
- None.
Insights
Schedule 13G/A shows a 9.99% passive stake in Opus Genetics.
Nantahala Capital Management and principals Wilmot B. Harkey and Daniel Mack disclose beneficial ownership of 7,123,506 Opus Genetics shares, or 9.99% of the common stock as of December 31, 2025. The position includes warrants exercisable within sixty days, indicating both current and near-term potential equity exposure.
The filing classifies the position as held in the ordinary course of business and explicitly not for the purpose of changing or influencing control. Voting and dispositive powers are shared and exercised through investment funds and separately managed accounts, with Blackwell Partners LLC - Series A entitled to proceeds on more than five percent of the class.
For investors, this establishes Nantahala as a sizable but passive institutional holder near the 10% threshold. Future ownership updates, if any, would be reflected in subsequent beneficial ownership filings rather than through operational announcements.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake does Nantahala hold in Opus Genetics (IRD)?
Is Nantahala’s Opus Genetics (IRD) position considered passive or activist?
Who are the reporting persons in this Opus Genetics (IRD) Schedule 13G/A?
What role does Blackwell Partners LLC - Series A play in the Opus Genetics (IRD) stake?
AI-generated analysis. How Rhea-AI works. Not financial advice.